Heartflow has filed for an initial public offering.

The company recorded sales of $125.8 million and a net loss of $96.4 million last year, according to a filing with the Securities and Exchange Commission on Thursday.

It didn't disclose an expected number of shares or price for the offering.

Heartflow's platform uses artificial intelligence to diagnose and manage coronary artery disease. The company plans to use proceeds from the offering to fund sales, marketing, research and product development, including new products, it said.

The company intends to have its units listed on Nasdaq under the ticker HTFL.